HLA class II alleles (detected by DNA typing) were determined in 116 Caucasians with systemic sclerosis positive and negative for anticentromere autoantibodies (ACA). Significantly increased frequencies of HLA-DR5(DRw11) (P = 0.009) and the Dw13(DRB1*0403, *0407) subtypes of DR4 (probability corrected, Pc = 0.005) were seen in ACA positive patients, and HLA-DR1 and DRw8 were also increased. These findings appeared to reflect linkage disequilibrium of DR5(DRwll) and many DR4(Dw13) haplotypes with HLADQw7 and DRi with DQw5. In fact, the presence of a DQB1 allele having a polar glycine or tyrosine at position 26 of the DQB1 first domain versus a hydrophobic leucine accounted for 100% of ACA positive Caucasian systemic sclerosis patients compared to 69% ofthe ACA negative SS patients (P = 0.0008) and 71% of Caucasian controls (P = 0.0003) as well as all 7 ACA patients of non-Caucasian background. Furthermore, the genotype frequency of DQB1 alleles lacking leucine at position 26 was 73% in ACA positive SS patients, compared to 42% of ACA negative patients (P = 1.2 X 10-`) and 38% of controls (P = 5.8 X 10-7). These data, then, suggest that the second hypervariable region of the HLA-DQB1 chain may form the candidate epitope associated with the ACA response. (J.
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1. Abbreviations used in this paper: ACA, anticentromere antibodies; OR, odds ratio; Pc, probability corrected; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SS, systemic sclerosis. those with widespread systemic fibrosis with critical pulmonary, cardiac, gastrointestinal, and renal involvement. SS is also a serologically heterogeneous disease with several highly disease-specific autoantibodies associating with certain clinical subsets. For example, anticentromere antibodies (ACA) are associated with limited skin and visceral involvement, including the CREST variant (subcutaneous calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) which usually protends a better prognosis (1) (2) (3) (4) (5) (6) (7) (8) . Anti-topoisomerase I antibodies (anti-Scl-70) have been correlated with widespread skin and systemic disease (7) (8) (9) . The presence of anti-PM-Scl, one of the anti-nucleolar antibodies, as well as anti-U I-RNP, have been associated with myositis, which occasionally occurs in SS patients (10) .
While the cause ofSS is unknown, both environmental and genetic factors have been implicated in pathogenesis. Ascertainment ofthe latter has resulted in a number ofstudies examining genetic markers, especially those encoded by genes ofthe major histocompatibility complex. A variety of studies have reported associations of SS with class I MHC specificities, includingHLA-A9 (11, 12) , B8 (13, 14) , andB35 (15, 16) ; class II MHC, including HLA-DRl (16) (17) (18) (19) , DR3 (14, 20) and DR5 (19, (21) (22) (23) ; and class III MHC, specifically C4 null alleles (15, 22) . These associations have been generally weak and inconsistent between different centers, and some investigations have even been unable to show any significant HLA associations with SS (24) (25) (26) (27) (28) (33) ; 10 sg was digested with the restriction endonucleases BamH 1 and TaqI under conditions specified by the manufacturer, and then electrophoresed through an 0.8% agarose gel overnight at 50 V. The gel was then stained in ethidium bromide, photographed, subjected to denaturation and neutralization as described previously (34) , and then transferred on to Zetabind membranes. (Cuno, Inc., Meriden, CT).
Probes used in this study included a 770 bp SacI/HindIII-cut fulllength DRBI cDNA (35) , a 700 bp full-length PstI-cut DQB1 cDNA (36) and a 2.4 kb genomic PstI cut DQA1 probe (37) which were radiolabeled with a CTP32 by oligolabeling (38) . Prehybridization and hybridization conditions were carried out as previously described (34) .
HLA-DR and DQ specificities were assigned to specific RFLP bands at the 10th International Histocompatibility Testing Workshop (IHTW) (39) , as well as in our own (40, 41) 18-mer oligonucleotide probes, supplied by the 1th International Histocompatibility Testing Workshop, were used to detect polymorphic sequences around positions 70 and 86 ofthe DRB1 first domain to distinguish DRBI*0I01, *0102 and *0103 and DRBl*l 101, *1 102, * 1 103 and *1 104. HLA-DR4 subtypes were determined using primers described previously (49) as well as conditions and oligonucleotide probes previously published (50).
For HLA-DQAI typing, genomic DNA was amplified with the primer pair DQAAMP-A (5-ATGGTGTAAACTTGTACCAGT-3') and DQAAMP-B (5TrGGTAGCAGCGGTAGAGTTG-3') under conditions outlined for DRB, except the extension step for the PCR was for 1 min at 550C. Oligonucleotide probes corresponding to the polymorphisms at positions 25, 34, 55 , and 69 were used forthe hybridizations as supplied by the 11th International Histocompatibility Testing Workshop.
For HLA-DQBl typing, the primers used included DQBAMP-A (5'CATGTGCTACTTCACCAACGG-3) and DQBAMP-B (5'-CTG-GTAGTTGTGTCTGCACAC-3) under the same PCR conditions as the DQA1 primers. Oligonucleotide probes corresponding to the polymorphic codons 26, 37, 45, 49, 57, and 70 were used for dot blot hybridization.
HLA-DPBl typing was carried out with the primers DPBAMP-A (5'-GAGAGTGGCGCCTCCGCTCAT-3') and DPBAMP-B (5'-GC-CGGCCCAAAGCCCTCACTC-3'), using the same PCR conditions as for HLA-DR5. 18-mer oligonucleotide probes corresponding to the polymorphic codons 9, 35, 55, 69, 76, and 85 were used for the dot blot hybridizations. Statistical analyses. Comparisons of HLA specificities and allelic frequencies in ACA positive verses ACA negative SS patients and versus normal race-matched controls were performed using the chi square analysis of2 X 2 tables and Yates' correction with the EPI-INFO statistical program. Significant P values were corrected (Pc) by multiplying the number of comparisons, i.e., for DR specificities x 12, DR4-Dw subtypes X 5, DQ specificities X 8, DQA1 alleles x 7, DQB1 alleles x 12, and DPB1 alleles x 19. Where an association with a particular specificity had been reported previously, the P value was not corrected.
Relative risks were calculated as odds ratios (OR).
Results
ACA were present in 42 (36%) ofthe Caucasian SS patients, but were infrequent in patients of other races. Examination of HLA-DR specificities showed HLA-DR5 (DRwl 1) to be significantly increased in Caucasians with ACA compared to normal controls (P = 0.009, OR = 4) ( Table I) , although no significant differences were seen when compared to ACA negative SS patients. HLA-DR1, and to a lesser degree HLA-DR4 and DRw8, were also more frequent, but not significantly so. In fact, HLA-DRI, DR4, DR5(DRw1 1) and/or DRw8 occurred in 93% of ACA positive patients compared to 68% of ACA negative SS patients (P = 0.003, OR = 6.4) and 58% of controls (P = 1.3 X 10-4, OR = 9.6). Also seen was a decreased frequency of HLA-DR3(DRw17) which was only significant when compared to ACA negative SS patients (Pc = 0.04).
Given the weak association of ACA with HLA-DR5(DRwI 1), as well as previous studies showing correlations of ACA with HLA-DR1 and DR4 (29) , oligotyping for HLA-DRB1 alleles was performed on all HLA-DR1, DR4 and DR5(DRw1 1) positive patients and controls. The frequencies of DRB1*0101, *0102 and *0103(DR1), and DRB1*1 101, *1102, *1103, and *1 104(DR5), were equivalent in ACA positive and negative SS patients and controls (data not shown). On the other hand, the HLA-Dwl 3 subtype of DR4, including the In order to test the relative strengths of the associations of HLA-DR5(DRwl 1) and DQw7 with the ACA response, we tested the presence vs. absence of one of the HLA-specificities in patients and controls in individuals with and without the other HLA-specificity, as proposed by Svejgaard and Ryder (51) . All HLA-DR5 (DRw1 1) positive Caucasian patients and controls also had HLA-DQw7. However, in DR5 (DRwl 1) negative individuals, DQw7 occurred in 34% of ACA positive patients, compared with 16% of ACA negative SS patients (P = 0.08) and 24% of controls (P = 0.4). We also found HLADQw7 to be associated with the antitopoisomerase I response (data not shown, manuscript in preparation). Accordingly, if anti-topoisomerase I positive SS patients were considered separately, the frequency ofHLA-DQw7 in the DR5(DRwl 1) negative, ACA negative group of SS patients fell to 11% (P = 0.055 compared to ACA positive patients), suggesting the HLADQw7 association with ACA to be independent of HLA-DR5(DRwl 1).
Typing for HLA-DQAl alleles (Table II) showed only a weak increase of frequency of DQA1*0101, found on most HLA-DQw5 heterodimers, compared to ACA negative SS patients and controls (P < 0.04, uncorrected, OR = 2.4). HLA-DQB1 allele determinations showed an increase in the frequency of DQB1*0301 (found only on DQw7 haplotypes) compared to controls (P = 0.02, OR = 2.6). HLA-DQB1*0501 (54), located in the floor of the putative peptide-binding groove in the second hypervariable region (55). Instead, these DQB1 alleles have either tyrosine or glycine at this position, both polar non-charged amino acids. Furthermore, the three ACA positive patients lacking DQwS and DQw7 had DQB1 *0601 or *0402 alleles, which also have tyrosine or glycine, respectively, at position 26. In total, therefore, the presence of one or more of these non-Leu-26 DQB1 alleles accounted for 100% of the Caucasian ACA positive patients, compared to 69% ofthe ACA negative SS patients (P = 0.0008) and 71% of the controls (P = 0.0003). This association was further underscored by examining genotype frequencies of non-Leu-26 DQB1 alleles, where non-Leu-26 alleles accounted for 73% of 84 HLA-DQB1 genotypes in ACA patients compared to 42% of 148 in ACA negative PSS patients (P = 1.2 X l0-5) and 38% of 158 in controls (P = 5.8 X l0-7). In fact, 43% ofACA positive SS patients had both oftheir DQB1 alleles lacking Leu-26, compared to 7% of ACA negative SS patients (P = 1 X l0-) and 14% of controls (P = 4 X 10-4) (Table III) . This might suggest a gene dosage effect, however homozygosity for these DQB1 alleles occurred no more frequently than would be expected by Hardy Weinberg equilibrium (43% vs 50%, P = NS). The association with non-Leu-26 alleles persisted even when the HLA-DR5(DRwl 1) positive individuals were removed, being present in 100% of the remaining ACA positive SS patients compared with 59% ofDR5 negative, ACA negative SS patients (P = 1.6 X l0-4) and 59% ofDR5 negative controls (P = 1.2 x 10-4).
As far as any possible protective role against developing ACA for the presence of leucine at position 26 of the DQB1 first domain is concerned, it should be noted that the frequency ofhaving one non-Leu-26 allele was the same (57%-61 %) in all groups studied, making this unlikely.
Regional differences in HLA-class II gene frequencies could at least in part explain the marked predominance of certain HLA-DQ alleles in ACA positive versus negative SS patients and controls, especially because the Caucasian controls here examined by RFLP and oligotyping were Houston medical students and health care workers ofpreponderantly Northern European ancestry. In fact, the frequency of HLA-DQw5 and DQw7 (determined by RFLP only) among 83 Caucasian controls from Ottawa was nearly twice that seen in Houston (R. Goldstein, unpublished data). HLA-class II gene frequencies from Miami controls were not available. However, the fre- quencies of Leu-26 negative DQB 1 alleles between ACA positive and negative SS patients was similar in all three regions. The most significant differences were seen between the larger numbers of ACA positive (n = 20) and negative (n = 30) Caucasian SS patients from Houston, where the non-Leu-26 DQB 1 genotypic frequencies were 80% vs 36% (P = 4 X I0-, OR = 7). Among those from Ottawa (14 ACA positive, 19 ACA negative) the genotype frequencies were 64% vs 34% (P = 0.03, OR = 3.5). The number ofACA positive patients from Miami was small (n = 5) vs those ACA negative, (n = 22). Nevertheless, the frequency of non-Leu-26 DQB1 alleles was 80% vs 48% (P = 0.086, OR = 4.4). HLA-DQw5 and DQw7 were more frequent in ACA positive versus negative SS patients from all regions, although the differences did not achieve statistical significance, perhaps due to the smaller numbers examined. All of seven other ACA positive patients of non-Caucasian ethnic origin also possessed non-Leu-26 DQB1 alleles, the majority having two. The one American black SS patient with ACA had HLA-DR5(DRwl 1), DQw7; DRw8, DQw4. Two additional American blacks with polymyositis also had ACA, one having HLA-DRl, DQw5; DR4(Dw13), DQw7 and the other DRl, DQw5; DRw8, DQw7. The Hispanic SS patient with ACA had DR1, DQw5 and DR4(Dw13), DQw8, as did both an ACA positive Hispanic with Sjogren's syndrome and another with dermatomyositis. A Chinese SS patient had HLADRw1O, DQw5; DRwl4, DQw5.
Discussion
Previous studies have examined HLA-DR specificities in SS patients with the ACA response, finding associations with the broad specificities HLA-DRl (8, 29) , DR4 (29), DR5(DRwl 1) (23), and possibly DRw8 (29) . Our earlier preliminary data, examining smaller numbers ofpatients than in this study, suggested weak associations of ACA with HLA-DRl and DR4 (56) . The amino acid sequence shared by DRl and the Dw14 (DRB 1 *0404, *0408) subtype of DR4, (QRRAA), which comprises residues 71-74 in the third hypervariable region of DRB1, was postulated to form an "epitope" predisposing to this autoantibody response. Subsequent DR4 subtyping, however, showed that only the Dw13(DRBl*0403, *0407) subtype was increased in frequency, and, in fact, that Dwl4(DRB 1*0404, *0408) was less common in the ACA positive SS patients. HLA-DR4(Dw 13) has a glutamic acid residue at position 74 of the DRB1 first domain, which is negatively charged, whereas DRI and DR4(Dw14) have an alanine, which is a hydrophobic residue, at this position. Thus DRI and DR4(Dw1 3) would be expected to have significant physiochemical differences in this segment ofthe third hypervariable region, which could have a major impact on antigen and/or T cell receptor interactions. Furthermore 
